{"meta":{"id":"https:\/\/api.iclient.ifeng.com\/ipadtestdoc?aid=ucms_81dApp3Z46d","type":"doc","o":"1","documentId":"ucms_81dApp3Z46d"},"body":{"newStatus":"1","documentId":"ucms_81dApp3Z46d","staticId":"ucms_81dApp3Z46d","title":"基石药业新药进展","shareTitle":"基石药业新药进展","thumbnail_doc":"","thumbnail":"","source":"","author":"","editorcode":"weMedia","editTime":"2020-11-23 13:51:21","updateTime":"2020\/11\/23 13:51:21","wapurl":"http:\/\/\/\/finance.ifeng.com\/c\/81dApp3Z46d","introduction":"","wwwurl":"http:\/\/\/\/finance.ifeng.com\/c\/81dApp3Z46d","commentsUrl":"ucms_81dApp3Z46d","commentCount":0,"text":"
每经AI快讯,基石药业(02616,HK)宣布在二零二零年欧洲肿瘤内科学会亚洲年会在线年会上以口头报告形式首次公布了 GEMSTONE-302 研究详细结果。结果显示舒格利单抗联合化疗较安慰剂联合化疗,作为晚期非小细胞肺癌(NSCLC)一线治疗,显著延长了研究者评估的无进展生存期(PFS)。结果达到统计学显著性,且有临床意义。舒格利单抗联合化疗的安全性良好,未发现新的安全性信号。<\/p>
(记者 袁东)<\/p>","img":[],"summary":"每经AI快讯,基石药业(02616,HK)宣布在二零二零年欧洲肿瘤内科学会亚洲年会在线年会上以口头报告形式首次公布了GEMSTONE-302研究详细结果。结果显","sharesummary":"每经AI快讯,基石药业(02616,HK)宣布在二零二零年欧洲肿瘤内科学会亚洲年会在线年会上以口头报告形式首次公布了GEMSTONE-302研究详细结果。结果显","commentType":"0","wemediaEAccountId":"373005","showclient":"0","shareurl":"https:\/\/ishare.ifeng.com\/c\/s\/v002gf4H1630ML2xhHk3NKHeQQxyCrWP3--qDD--dUe16bwLw__","praise":"0","like_num":"0"}}